Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CELC
STRONG SELLCelcuity Inc. · Healthcare · United States · $4.0B · Avg Vol: $134M/d
COMPANY DESCRIPTION
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for oncology, utilizing its proprietary CELsignia companion diagnostic platform. The platform analyzes live tumor cells from patients to identify active signaling pathways, enabling more precise patient selection for its lead drug candidate, gedatolisib. Celcuity's competitive moat is built on this integrated approach of combining functional cellular diagnostics with targeted therapeutic development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 38.9M | 417.1M | — |
| EPS | -1.17 | -2.69 | -2.83 | -3.79 | — | -3.88 | -3.77 | 0.96 | — |
| Shares | 48.8M | 25.5M | 37.1M | 48.2M | -1.1% | 48.8M | — | — | — |
| Debt | 35.2M | 37.4M | 98.0M | 321.9M | 109.0% | 323.4M | — | — | — |
| Equity | 133.8M | 139.8M | 115.6M | 100.6M | -9.1% | — | — | — | — |
| Op CF | -36.0M | -53.8M | -83.5M | -153.3M | — | -172.5M | — | — | — |
| Inv CF | -144.0M | -5.0M | -63.1M | -64.1M | — | — | — | — | — |
| Fin CF | 120.3M | 64.9M | 138.4M | 360.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CELC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CELC | Celcuity Inc.(you) | $4.0B | 14 | STRONG SELL |
| GPCR | Structure Therapeutics Inc. | $3.5B | 15 | STRONG SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 20 | SELL |
| SRRK | Scholar Rock Holding Corporation | $5.7B | 13 | STRONG SELL |
| MANE | Veradermics, Incorporated | $4.6B | 8 | STRONG SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| PBLS | Parabilis Medicines, Inc. | $3.8B | 5 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 15 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%